智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司全资子公司九洲生物医药(台州)有限公司 (原"浙江四维医药科技有限公司")收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片的《药品注 册证书》。 甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治 疗或预防深静脉血栓和肺栓塞。甲苯磺酸艾多沙班片最早由日本第一三共研发，于2011年4月在日本上 市。目前国内获得该药品注册证书的生产厂家为海南先声药业有限公司、山东新时代药业有限公司等。 ...

甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治 疗或预防深静脉血栓和肺栓塞。甲苯磺酸艾多沙班片最早由日本第一三共研发，于2011年4月在日本上 市。目前国内获得该药品注册证书的生产厂家为海南先声药业有限公司、山东新时代药业有限公司等。 九洲药业（603456）(603456.SH)发布公告，近日，公司全资子公司九洲生物医药(台州)有限公司(原"浙 江四维医药科技有限公司")收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片的《药品注册证 书》。 ...

截至发稿，葛兰累计任职时间10年293天，现任基金资产总规模435.44亿元，任职期间最佳基金回报 109.26%， 任职期间最差基金回报-35.13%。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 从九洲药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居九洲药业十大流通股东。中欧医疗健康混合A（003095）三季度 增持397.67万股，持有股数1740.3万股，占流通股的比例为1.96%。根据测算，今日浮盈赚取约1879.52 万元。连续4天上涨期间浮盈赚取1583.67万元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益24.47%， 同类排名3925/8140；近一年收益13.31%，同类排名4906/8056；成立以来收益114.81%。 11月14日，九洲药业涨5.31% ...

Core Points - The ownership structure of Jiuzhou Pharmaceutical has changed, with Huaxuande no longer holding shares in Zhongbei Group and Taizhou Gede, leading to a new actual controller structure involving Huali Rong and Huaxiao Hui [2][3] - Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4] Group 1 - Huaxuande transferred 28.50% of Zhongbei Group's shares to Huali Rong and 14% to Huaxiao Hui, with total payments amounting to 61.815 million yuan [2] - Following the transfer, Huali Rong holds 22.17% and Huaxiao Hui holds 13.36% of Jiuzhou Pharmaceutical indirectly [2] - The market value of Jiuzhou Pharmaceutical shares held by Zhongbei Group and Taizhou Gede is estimated at approximately 24.76 billion yuan [2] Group 2 - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [3] - Huaxuande, aged 82, stepped down as chairman in 2014, with his daughter Huali Rong succeeding him [3] - Huali Rong has held various leadership roles and was recently elected as the executive director and legal representative of Jiuzhou Pharmaceutical [3] Group 3 - Huaxuande and his family's wealth was ranked 338th on the Hurun Rich List in 2020 with 16 billion yuan, and they are currently ranked 2750th and 940th on the global and national rich lists, respectively [4] - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [4]

Core Viewpoint - The control of Jiuzhou Pharmaceutical has changed due to the transfer of shares from the aging actual controller, Hua Xuande, to his daughters, Hua Lirong and Hua Xiaohui, which will not affect the company's operational independence or business performance [2][4]. Group 1: Share Transfer Details - Hua Xuande transferred 42.50% of his shares in Zhongbei Group and 10.00% in Taizhou Gede to his daughters, with Hua Lirong receiving 28.50% and Hua Xiaohui 14% of Zhongbei Group, and each receiving 5% of Taizhou Gede [1]. - The total payment for the share transfer was 61.815 million yuan, with Hua Lirong paying 41.333 million yuan and Hua Xiaohui 20.482 million yuan [1]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's closing price of 19.88 yuan per share, is approximately 2.476 billion yuan [1]. Group 2: Company Background and Performance - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule chemical drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [4]. - The company reported a revenue of 4.16 billion yuan for the first three quarters of the year, representing a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4]. - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [5].

其中，28.50%中贝集团股权转让给花莉蓉，14%转让给花晓慧；台州歌德股权由花莉蓉、花晓慧各自受 让5%。花莉蓉、花晓慧受让上述股权支付的对价分别为4133.3万元、2048.2万元。 此次调整后，公司控股股东未发生变化，花轩德将不再持有中贝集团、台州歌德的股权，同时不再间接 持有上市公司股票。花莉蓉将直接持有中贝集团51.00%股权、台州歌德5.00%股权；花晓慧将直接持有 中贝集团36.50%股权、台州歌德5.00%股权。 【#82岁富豪将近25亿元股票分给两女#，花轩德拟彻底退隐】 据红星资本局报道，11月12日，九洲药业昨日公告称，公司于近日收到控股股东浙江中贝九洲集团（下 称"中贝集团"）及其一致行动人台州歌德的《告知函》，花轩德因年事已高，拟将其持有的中贝集团 42.50%股权、台州歌德10%股权转让给女儿花莉蓉和花晓慧。 截至目前，中贝集团、台州歌德分别持有九洲药业股票2.8352亿股、4058.568万股。以九洲药业截至11 月11日的收盘价（19.88元/股）估算，上述股票对应的市值分别为56.36亿元、8.07亿元。以此估算，花 轩德转让的两笔股权间接持有九洲药业股票的市值合计约24.7 ...

每经记者｜陈星 每经编辑｜程鹏 文多 11月11日，九洲药业（SH603456）披露，实控人之一花轩德将持股转让给女儿花莉蓉和花晓慧。转让完成后，花轩德将不再持有上市公司股份，花莉蓉 直接和间接持有九洲药业22.17%股权，花晓慧间接持有九洲药业13.36%股权。九洲药业实控人由花轩德、花莉蓉、花晓慧减少为花莉蓉、花晓慧。 九洲药业公告称，花轩德是因本人年事已高退出实控人行列。而花轩德最近一次被资本市场注意，还与最近颇受关注的北大医药控股股东重组事项有关。 花轩德（资料图），图源："同心聚椒"微信公众号 花轩德"清空"九洲药业持股 11月11日，九洲药业公告实控人调整。原实控人之一花轩德退出实控人行列。 具体股权调整为，花轩德将其持有的浙江中贝九洲集团有限公司（以下简称"中贝集团"）42.5%股权、台州市歌德实业有限公司（以下简称"台州歌德"） 10%股权分别转让给女儿花莉蓉和花晓慧。 其中，28.50%中贝集团股权转让给花莉蓉，14%转让给花晓慧；台州歌德股权由花莉蓉、花晓慧各自受让5%。花莉蓉、花晓慧受让上述股权支付的对价 分别为4133.3万元、2048.2万元。 本次转让完成后， 花轩德将不持有中贝集 ...

Group 1 - The board of directors of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. held its 18th meeting of the 8th session on November 12, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][4] - The board approved the election of Ms. Hua Lirong as the representative director to execute company affairs and as the legal representative, with her term lasting until the end of the current board's term [3][4] - The board also approved the election of members for the audit committee, including Ms. Jiang Qi, Mr. Yang Lirong, and Mr. Li Jicheng, with Ms. Jiang serving as the committee's convener [5][6] Group 2 - The audit committee is composed of a majority of independent directors, complying with relevant laws and regulations [5] - The term for the newly elected audit committee members will also last until the end of the current board's term [5]

Group 1 - The company announced the convening of the eighth employee representative assembly on November 12, 2025 [2] - During the assembly, employees voted to remove Mr. Chen Jinkang from his position as employee supervisor [2] - Ms. Chen Liyue was elected as the employee representative director for the company's eighth board of directors [2]

Core Viewpoint - The actual controller of Jiuzhou Pharmaceutical, Hua Xuande, has transferred his shares to his daughters, resulting in a change in the company's control structure, primarily due to Hua's advanced age [2][3][4]. Share Transfer Details - Hua Xuande transferred 42.5% of his shares in Zhejiang Zhongbei Jiuzhou Group and 10% in Taizhou Gede Industrial to his daughters, Hua Lirong and Hua Xiaohui [3][4]. - After the transfer, Hua Lirong holds 22.17% of Jiuzhou Pharmaceutical directly and indirectly, while Hua Xiaohui holds 13.36% indirectly [2][3]. Financial Aspects - The total value of the shares transferred from Zhongbei Group was 61.115 million yuan, and the shares from Taizhou Gede were valued at 700,000 yuan [4]. Background Information - Hua Xuande, born in 1943, is 82 years old and has gradually stepped back from management roles in Jiuzhou Pharmaceutical over recent years [5][9]. - The company was founded focusing on the research, production, and sales of chemical raw materials and pharmaceutical intermediates, later transitioning to contract custom development and production [9]. Control Structure Post-Transfer - Following the transfer, the actual controllers of Jiuzhou Pharmaceutical are now Hua Lirong and Hua Xiaohui, with Zhongbei Group remaining the controlling shareholder [4][8].